Login to Your Account

Chiron Buying Matrix For $61M, Adding Tezacitabine To Pipeline

By Brady Huggett

Tuesday, January 8, 2002
Chiron Corp., its eyes firmly focused on the cancer therapeutic tezacitabine, is acquiring Matrix Pharmaceutical Inc. for $61 million in cash.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription